Fibrogen INC 8-K filings

FibroGen reports a 14% revenue increase driven by roxadustat sales in China, while implementing a significant cost reduction plan in the U.S. due to disappointing pancreatic cancer trial results.

FibroGen presented an update on the clinical development program for FG-3246, a novel antibody-drug conjugate targeting CD46, for metastatic castration-resistant prostate cancer (mCRPC).

FibroGen's stockholders approved the 2024 Equity Incentive Plan and elected three Class I directors at the company's annual meeting on June 5, 2024.

FibroGen's first quarter revenue increased by 55% year-over-year, driven by strong roxadustat sales in China and a one-time revenue recognition from the AstraZeneca agreement termination.

FibroGen announced its 2023 financial results, highlighted by increased revenue in China and a cost reduction plan, while also anticipating key clinical trial data in 2024.